Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Antithymocyte immunoglobulin rabbit** is a rabbit-derived polyclonal immunoglobulin G preparation produced by immunizing rabbits with human thymocytes. It contains cytotoxic antibodies against multiple T-lymphocyte surface antigens and produces broad T-cell depletion and immunosuppression through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, apoptosis, and modulation of T-cell activation and trafficking. Marketed as **Thymoglobulin**, it is approved for prophylaxis and treatment of acute kidney-transplant rejection when used with concomitant immunosuppression. It is supplied as a lyophilized powder for intravenous infusion and is also used in transplant-conditioning and graft-versus-host disease prevention protocols. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antithymocyte immunoglobulin rabbit.